A group of researchers lead by Min Ae Lee-Kirsch from the Department of Pediatrics, Medical Faculty, TUD Dresden University of Technology (Germany), studied four patients from two families who developed symptoms of SLE in the first years of life. As familial occurrence of SLE in young children is highly unusual, her team searched for a primary genetic cause and found a mutation in the UNC93B1 gene in all affected family members.
Dr. John Cush RheumNow
2 years 7 months ago
Hormonal Status Increases RA Risk
Early menopause—before the age of 45—taking hormone replacement therapy (HRT), and having 4 or more children are among several hormonal and reproductive factors linked to a heightened risk of RA in women.
https://t.co/Rz6rzkOHV5 https://t.co/UYjgs0MBv5
Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.
2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.
Dr. John Cush RheumNow
2 years 7 months ago
Full read review of Catastrophic Antiphospholipid Syndrome (CAPS) https://t.co/J1kOJYv1Cl https://t.co/cJQagQmEp6
Dr. John Cush RheumNow
2 years 7 months ago
Retrospective study 127 suspected #GCA w/ negative temporal artery Bx - 73 finally Dx w/ GCA & 61/73 were FDG PET-CT pos.(84%). In 54 nonGCA, FDG PET-CT was positive in 8 (15%). FDG-PET sensitivity 84% (100% extracranial LV-GCA), specificity of 85%. https://t.co/Uc8dbdzIil https://t.co/z2d7h6jCFP
A cohort study suggest that patients with dermatomyositis (DM) are at an increased risk for multiple comorbidities, including chronic kidney and cardiovascular disease,
Dr. John Cush RheumNow
2 years 7 months ago
Insurance claims data compared 33k RA to 1079 PM/DM pts and showed overall lower use of statin R in PM/DM (27% vs 181%, p<0.0001). But if DM/PM-HLD pts used statins they had lower mortality rate than non-users (HR = 0.515, p = 0.0273) https://t.co/El0mmNZ8ZR https://t.co/428YmGlV5k
Dr. John Cush RheumNow
2 years 7 months ago
Real-world data of 5070 RA pts (1816 Rx w/ b/tsDMARDs) showed the use of tsDMARD considerably increased from 2012 to 2021. All b/tsDMARDs pts improved Dz activity & function/ 10 yr effiicacy best for IL6Ri in switch pts and ABA in bNAIVE pts https://t.co/H4Ohe12LrV https://t.co/viUdiZvxVa
Dr. John Cush RheumNow
2 years 7 months ago
Metanlysis of 49 studies, 10 RCTs examined the relationship between RA and non-surgical Rx of periodontitis (NSRT) and in general short term studies show that NSPT benefits RA patients; and DMARD therapy benefits periodontitis https://t.co/ApKUipFzYn https://t.co/qw6SYn1tBf
A JAMA Dermatology systematic review of drug-induced dermatomyositis (DM) found the most commonly implicated agents include hydroxyurea, immune checkpoint inhibitors, statins and lipid-lowering agents, penicillamine, and tumor necrosis factor inhibitors.
Dr. John Cush RheumNow
2 years 7 months ago
Black, Asian, and Hispanic Military Members w/OA Treated Differently
Black, Asian, and Hispanic members of the U.S. Armed Forces were less likely than their white peers to undergo knee replacement surgeries post OA diagnosis, military researchers found.
https://t.co/Kzj4XyCmZt https://t.co/TwBAtn9Dwr
Dr. John Cush RheumNow
2 years 7 months ago
ICYMI: When PMR Strikes Young, It Hits Hard
https://t.co/rUuPnbcgCY https://t.co/AMpqGCJhIa
Dr. John Cush RheumNow
2 years 7 months ago
2023 In Memoriam
In 2023, too many of our rheumatology colleagues passed away. Here is an incomplete list of our revered fellow practitioners, mentors, role-models, and researchers.
https://t.co/FS4K7TUPKh https://t.co/xufTgjpOzl
Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.
